AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2025
Aug 20, 2025
30604_dirs_2025-08-19_a52b4814-06d7-4cf3-b2c7-55697d13fab0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-08-16
Reporting Person: Trimarchi Thomas (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-08-16 | Common Stock | F | 21317 | $51.32 | Disposed | 480671 | Direct |
| 2025-08-18 | Common Stock | S | 15380 | $50.1437 | Disposed | 465291 | Direct |
| 2025-08-18 | Common Stock | S | 1973 | $50.9439 | Disposed | 463318 | Direct |
Footnotes
F1: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 38,547 shares of Common Stock underlying the Reporting Person's Restricted Stock Units.
F2: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.
F3: Represents the weighted average sale price of the shares sold from $49.76 to $50.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F4: Represents the weighted average sale price of the shares sold from $50.83 to $50.95 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.